Korea's Cosmetics Industry Promotion Act: Who the "Innovative Cosmetics Company" Certification Will Actually Reward
- 12 hours ago
- 6 min read
Korea's National Assembly passed the Act on the Fostering and Support of the Cosmetics Industry on 20 August 2026. The only genuinely new instrument in it — certification as an "innovative cosmetics company" — has its qualifying thresholds left entirely to presidential decree. That means the law that decides who benefits will be written over the next twelve months, not last week, and if it is written as an R&D-spending gate it will certify the manufacturers and miss the exporters.
What does Korea's Cosmetics Industry Promotion Act actually do?
It gives the Ministry of Health and Welfare a standing mandate over cosmetics as an industry, running alongside the Ministry of Food and Drug Safety's existing mandate over cosmetics as a safety question under the Cosmetics Act. Korea now has two ministries with two opposite jobs on the same product: one polices it, one promotes it.
The mechanics are conventional. The health minister draws up a five-year comprehensive plan, confirmed by a new committee sitting under him. A state-of-the-industry survey runs every three years. There are provisions for industry clusters, a comprehensive support centre, an integrated information system, specialist workforce training, support for the packaging and raw-material tiers, and trademark cooperation with major export markets. The Act takes effect one year after promulgation, which itself follows cabinet deliberation.
Read that list again and notice how much of it already exists. The Korea Health Industry Development Institute (KHIDI) and the Korea Cosmetic Industry Institute have both run cosmetics support programmes for years — the Korean trade press covering the bill notes that the ministry's cosmetics policy is currently split between the two, and that sorting out which body does what is now the live administrative question.
Plans, committees, portals and centres are the standard furniture of Korean industrial policy. They get built, they publish, and the export figure does what it was going to do anyway.
What is the "innovative cosmetics company" certification?
It sits in Article 16, and it is the one genuinely new instrument in the Act.
A company qualifies by investing above a set threshold in cosmetics R&D, or by meeting criteria related to overseas-expansion capability. Note the or. The Korean bill text is disjunctive — two independent routes — and everything below turns on that. Some English coverage has rendered it as R&D investment alongside export capacity, which reads as a single combined test. It is not one.
The health minister certifies, after deliberation by the new committee. Certification runs three years and carries preferential treatment in national and local government support programmes. KHIDI is named in the bill as the presumptive implementing agency for the certification function.
Then the sentence that matters: the investment threshold, the company categories and the support methods are all left to presidential decree.
So the law that passed on 20 August is a container. The decree drafted over the next twelve months is the law.
Why does the R&D investment threshold matter so much?
Because of who actually generates Korea's cosmetics export revenue.
Korean cosmetics exports hit USD 11.4 billion in 2025, a record year. The Ministry of Food and Drug Safety's provisional figure for the first half of 2026 is USD 7 billion, up 27.3 percent year on year and the highest first half on record. Over the same period, the share of total cosmetics exports made by small and medium-sized enterprises rose from 56.2 percent in 2022 to 72.8 percent in 2025.
That last number is the whole problem.
The companies producing close to three-quarters of the export value are indie brands, and the structural reason they can export at all is that they do not carry their own R&D. Kolmar Korea and Cosmax hold the formulation, the stability work and the technical dossiers. The brand holds the concept, the channel and the localising.
This is not a weakness in the model. It is the model. It is a good division of labour, and it is the reason a Korean brand can get from incorporation to a foreign retail shelf without ever owning a laboratory.
Now measure that company by R&D spend. It scores nothing.
Its ODM scores well — and in the third week of August 2026, Cosmax and Cosmecca Korea both came within touching distance of 52-week highs intraday, with Kolmar Korea climbing alongside them. That tier of the supply chain is not what is waiting on a certificate.
What happened when Korea tried this in pharmaceuticals?
We do not have to speculate about how an R&D-spending gate behaves, because Korea has already run this exact instrument.
The "innovative pharmaceutical company" certification has existed since 2012 under the Special Act on the Fostering and Support of the Pharmaceutical Industry. Same ministry. Same implementing agency.
This year the ministry raised the R&D-investment ratio requirement by two percentage points across the board — to 9 percent of pharmaceutical revenue for companies below KRW 100 billion in sales, and 7 percent for those above it — with a three-year grace period before the tightened requirement bites.
It also had to split the absolute-spending scoring band in two after industry consultation. The July draft criteria had applied a single band regardless of company size. Under the final rules, a company below KRW 100 billion in sales needs a three-year average of KRW 45 billion a year in R&D to reach the top grade; above that line, the top grade costs KRW 100 billion a year.
And clinical trials are weighted 5 for phase 3 against 0.7 for phase 1. Results, not intent.
Fourteen years in, that scheme is still recalibrating who counts as innovative — and still recalibrating in the direction of balance-sheet size. Every adjustment described above is an attempt to stop an absolute-spending measure from simply ranking companies by how large they already are.
Transposed to cosmetics unmodified, an R&D-spend gate certifies manufacturers and misses exporters. Not through any bad intent. Through the arithmetic of the measure itself.
What does "overseas expansion capability" mean?
Nothing yet. And that is the most consequential blank in the statute.
Written lazily, it becomes export revenue — which certifies whoever is already winning and directs support to the companies with the least need of it.
Written well, it measures what actually separates a brand with a foreign market from a brand with a foreign order:
Whether the product registration in the destination market is held by the brand or by its distributor.
Whether the Responsible Person under EU Regulation (EC) No 1223/2009 answers to the brand owner or to somebody else.
Repeat orders as a share of total orders.
Whether a distributor relationship survives its second year.
Those four things are the difference between an export figure and an export business, and none of them is currently collected anywhere. Which makes the three-yearly state-of-the-industry survey — easily the dullest clause in the Act — the one worth watching. What the survey measures is what the certification can eventually reward.
When does the Act take effect, and what should exporters do now?
The Act takes effect one year after promulgation. The consultation on subordinate legislation runs across that year, and the ministry has said it will gather views from industry, experts and other ministries before drafting the enforcement decree and enforcement rules.
That consultation is the event. Not the vote.
If your export capability is real but does not show up as an R&D line item on your accounts, the window in which that can be argued is open now and closes when the decree is finalised. The submissions that shape it will come from whoever bothers to make them, and the tiers most affected by an R&D-spending gate are also the tiers least likely to have anyone whose job is to file a policy comment.
The vote was the easy part.
Comments